Stay updated with breaking news from Malignant Hematology Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Watch Dr. Brandon J Blue, Dr. Surbhi Sidana, Dr. Kenneth H. Shain and Mary Derome answer questions about the future of treatment during the CURE Educated Patient Multiple Myeloma Summit.
Treatment of myelofibrosis focuses on alleviation of symptoms, management of cytopenias, and prevention of complications.
AbFero Pharmaceuticals Announces Initiation Of Phase 1 Study For Lead Iron Chelator Study to Examine Safety of SP-420 in MDS and MF News provided by Share this article Share this article BOSTON, Feb. 23, 2021 /PRNewswire/ -- AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, today announced the initiation of a Phase 1 study of its lead iron chelator, SP-420, in myelodysplastic (MDS) and myelofibrosis patients (MF) with transfusional iron overload (TIO). "The opening of this trial in MDS and MF marks anothe...